JP2006509781A - インドール−３−カルボキサミドの誘導体、それらの製造方法および治療用途 - Google Patents
インドール−３−カルボキサミドの誘導体、それらの製造方法および治療用途 Download PDFInfo
- Publication number
- JP2006509781A JP2006509781A JP2004556430A JP2004556430A JP2006509781A JP 2006509781 A JP2006509781 A JP 2006509781A JP 2004556430 A JP2004556430 A JP 2004556430A JP 2004556430 A JP2004556430 A JP 2004556430A JP 2006509781 A JP2006509781 A JP 2006509781A
- Authority
- JP
- Japan
- Prior art keywords
- group
- indole
- methyl
- formula
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LSGKMZLPZFPAIN-UHFFFAOYSA-N 1h-indole-3-carboxamide Chemical class C1=CC=C2C(C(=O)N)=CNC2=C1 LSGKMZLPZFPAIN-UHFFFAOYSA-N 0.000 title abstract description 5
- 230000001225 therapeutic effect Effects 0.000 title abstract description 3
- 238000000034 method Methods 0.000 title description 9
- 238000002360 preparation method Methods 0.000 title description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 125000005843 halogen group Chemical group 0.000 claims abstract description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 13
- 239000001257 hydrogen Substances 0.000 claims abstract description 13
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 10
- 125000004434 sulfur atom Chemical group 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 125000002837 carbocyclic group Chemical group 0.000 claims abstract description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 62
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 36
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 20
- -1 1,3,3-trimethylbicyclo [2.2.1] hept-2-yl Chemical group 0.000 claims description 14
- 239000012453 solvate Substances 0.000 claims description 11
- 229910052801 chlorine Inorganic materials 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 239000000460 chlorine Substances 0.000 claims description 8
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 6
- OAICLVYDZDGPST-UHFFFAOYSA-N 6,7-dichloro-1-[3-(methanesulfonamido)propyl]-2-methyl-n-(2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl)indole-3-carboxamide Chemical compound C12=CC=C(Cl)C(Cl)=C2N(CCCNS(C)(=O)=O)C(C)=C1C(=O)NC1C(C2)(C)CCC2C1(C)C OAICLVYDZDGPST-UHFFFAOYSA-N 0.000 claims description 5
- QKBDQOSMXRXTGL-UHFFFAOYSA-N 7-chloro-2-methyl-1-(3-methylsulfanylpropyl)-n-(2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl)indole-3-carboxamide Chemical compound C12=CC=CC(Cl)=C2N(CCCSC)C(C)=C1C(=O)NC1C(C2)(C)CCC2C1(C)C QKBDQOSMXRXTGL-UHFFFAOYSA-N 0.000 claims description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 208000002193 Pain Diseases 0.000 claims description 4
- 150000004677 hydrates Chemical class 0.000 claims description 4
- KMAKOBLIOCQGJP-UHFFFAOYSA-N indole-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CNC2=C1 KMAKOBLIOCQGJP-UHFFFAOYSA-N 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 125000006177 alkyl benzyl group Chemical group 0.000 claims 2
- 239000000126 substance Substances 0.000 abstract description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 34
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 23
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 16
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 229930003827 cannabinoid Natural products 0.000 description 10
- 239000003557 cannabinoid Substances 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 239000012429 reaction media Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- QPFMBZIOSGYJDE-UHFFFAOYSA-N 1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)C(Cl)Cl QPFMBZIOSGYJDE-UHFFFAOYSA-N 0.000 description 2
- XKAZULSGMADKFC-UHFFFAOYSA-N 7-chloro-1-[3-(methanesulfonamido)propyl]-2-methyl-n-(2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl)indole-3-carboxamide Chemical compound C12=CC=CC(Cl)=C2N(CCCNS(C)(=O)=O)C(C)=C1C(=O)NC1C(C2)(C)CCC2C1(C)C XKAZULSGMADKFC-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002475 indoles Chemical class 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical class ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- RNJRWVXVLDGRRS-UHFFFAOYSA-N 3-(3-methylsulfanylpropyl)-1,2-dihydroindole-3-carboxylic acid Chemical compound C1=CC=C2C(CCCSC)(C(O)=O)CNC2=C1 RNJRWVXVLDGRRS-UHFFFAOYSA-N 0.000 description 1
- FPYZJRUNMYOKDH-UHFFFAOYSA-N 6,7-dichloro-1-(3-methylsulfanylpropyl)-n-(2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl)indole-3-carboxamide Chemical compound C12=CC=C(Cl)C(Cl)=C2N(CCCSC)C=C1C(=O)NC1C(C)(C)C2CCC1(C)C2 FPYZJRUNMYOKDH-UHFFFAOYSA-N 0.000 description 1
- DCJHWOGXPMCTLD-UHFFFAOYSA-N 6,7-dichloro-1-(3-methylsulfonylpropyl)-n-(2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl)indole-3-carboxamide Chemical compound ClC1=CC=C2C(C(=O)NC3C4(C)CCC(C4)C3(C)C)=CN(CCCS(C)(=O)=O)C2=C1Cl DCJHWOGXPMCTLD-UHFFFAOYSA-N 0.000 description 1
- XAYNHMLFQDMFER-UHFFFAOYSA-N 6,7-dichloro-1-[3-(methanesulfonamido)propyl]-2-methylindole-3-carboxylic acid Chemical compound C1=C(Cl)C(Cl)=C2N(CCCNS(C)(=O)=O)C(C)=C(C(O)=O)C2=C1 XAYNHMLFQDMFER-UHFFFAOYSA-N 0.000 description 1
- AYEBMHBRCXVJQS-UHFFFAOYSA-N 6,7-dichloro-2-methyl-1-(3-methylsulfonylpropyl)-n-(2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl)indole-3-carboxamide Chemical compound C12=CC=C(Cl)C(Cl)=C2N(CCCS(C)(=O)=O)C(C)=C1C(=O)NC1C(C2)(C)CCC2C1(C)C AYEBMHBRCXVJQS-UHFFFAOYSA-N 0.000 description 1
- AFJSYVRDDKCNJU-UHFFFAOYSA-N 6,7-dichloro-n-(2,2-dimethylpropyl)-1-(3-methylsulfanylpropyl)indole-3-carboxamide Chemical compound C1=C(Cl)C(Cl)=C2N(CCCSC)C=C(C(=O)NCC(C)(C)C)C2=C1 AFJSYVRDDKCNJU-UHFFFAOYSA-N 0.000 description 1
- JHBIXZCSQMEACQ-UHFFFAOYSA-N 6,7-dichloro-n-(2,2-dimethylpropyl)-1-(3-methylsulfonylpropyl)indole-3-carboxamide Chemical compound ClC1=CC=C2C(C(=O)NCC(C)(C)C)=CN(CCCS(C)(=O)=O)C2=C1Cl JHBIXZCSQMEACQ-UHFFFAOYSA-N 0.000 description 1
- ZICLOZYWZBTBRC-UHFFFAOYSA-N 6,7-dichloro-n-(2-methylbutan-2-yl)-1-(3-methylsulfanylpropyl)indole-3-carboxamide Chemical compound ClC1=CC=C2C(C(=O)NC(C)(C)CC)=CN(CCCSC)C2=C1Cl ZICLOZYWZBTBRC-UHFFFAOYSA-N 0.000 description 1
- PJFYTRCJWRVJJH-UHFFFAOYSA-N 6,7-dichloro-n-(2-methylbutan-2-yl)-1-(3-methylsulfonylpropyl)indole-3-carboxamide Chemical compound ClC1=CC=C2C(C(=O)NC(C)(C)CC)=CN(CCCS(C)(=O)=O)C2=C1Cl PJFYTRCJWRVJJH-UHFFFAOYSA-N 0.000 description 1
- FEWFTMJIXJWUHW-UHFFFAOYSA-N 6,7-difluoro-1-[3-(methanesulfonamido)propyl]-2-methyl-n-(2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl)indole-3-carboxamide Chemical compound C12=CC=C(F)C(F)=C2N(CCCNS(C)(=O)=O)C(C)=C1C(=O)NC1C(C2)(C)CCC2C1(C)C FEWFTMJIXJWUHW-UHFFFAOYSA-N 0.000 description 1
- INQLKLQSVXPBNN-UHFFFAOYSA-N 6,7-difluoro-2-methyl-1-(3-methylsulfonylpropyl)-n-(2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl)indole-3-carboxamide Chemical compound C12=CC=C(F)C(F)=C2N(CCCS(C)(=O)=O)C(C)=C1C(=O)NC1C(C2)(C)CCC2C1(C)C INQLKLQSVXPBNN-UHFFFAOYSA-N 0.000 description 1
- RIHZWNIICABHMD-UHFFFAOYSA-N 7-bromo-1-[3-(methanesulfonamido)propyl]-2,6-dimethyl-n-(2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl)indole-3-carboxamide Chemical compound C12=CC=C(C)C(Br)=C2N(CCCNS(C)(=O)=O)C(C)=C1C(=O)NC1C(C2)(C)CCC2C1(C)C RIHZWNIICABHMD-UHFFFAOYSA-N 0.000 description 1
- FCCINWHEUFPQPA-UHFFFAOYSA-N 7-bromo-1-[3-(methanesulfonamido)propyl]-2-methyl-n-(2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl)indole-3-carboxamide Chemical compound C12=CC=CC(Br)=C2N(CCCNS(C)(=O)=O)C(C)=C1C(=O)NC1C(C2)(C)CCC2C1(C)C FCCINWHEUFPQPA-UHFFFAOYSA-N 0.000 description 1
- VZKWBERCKUMZOM-UHFFFAOYSA-N 7-bromo-2,6-dimethyl-1-(3-methylsulfonylpropyl)-n-(2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl)indole-3-carboxamide Chemical compound C12=CC=C(C)C(Br)=C2N(CCCS(C)(=O)=O)C(C)=C1C(=O)NC1C(C2)(C)CCC2C1(C)C VZKWBERCKUMZOM-UHFFFAOYSA-N 0.000 description 1
- YIKQKDQBBMSKPX-UHFFFAOYSA-N 7-bromo-2-methyl-1-(3-methylsulfonylpropyl)-n-(2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl)indole-3-carboxamide Chemical compound C12=CC=CC(Br)=C2N(CCCS(C)(=O)=O)C(C)=C1C(=O)NC1C(C2)(C)CCC2C1(C)C YIKQKDQBBMSKPX-UHFFFAOYSA-N 0.000 description 1
- POAVGUCMTJGXFI-UHFFFAOYSA-N 7-chloro-1-[3-(methanesulfonamido)propyl]-2,6-dimethyl-n-(2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl)indole-3-carboxamide Chemical compound C12=CC=C(C)C(Cl)=C2N(CCCNS(C)(=O)=O)C(C)=C1C(=O)NC1C(C2)(C)CCC2C1(C)C POAVGUCMTJGXFI-UHFFFAOYSA-N 0.000 description 1
- MONLLKFFFPRZNQ-UHFFFAOYSA-N 7-chloro-1-[3-(methanesulfonamido)propyl]-2-methyl-n-pentylindole-3-carboxamide Chemical compound C1=CC=C2C(C(=O)NCCCCC)=C(C)N(CCCNS(C)(=O)=O)C2=C1Cl MONLLKFFFPRZNQ-UHFFFAOYSA-N 0.000 description 1
- GKZQFQWWFWNLLK-UHFFFAOYSA-N 7-chloro-1-[3-(methanesulfonamido)propyl]-2-methylindole-3-carboxylic acid Chemical compound C1=CC(Cl)=C2N(CCCNS(C)(=O)=O)C(C)=C(C(O)=O)C2=C1 GKZQFQWWFWNLLK-UHFFFAOYSA-N 0.000 description 1
- BPRNDMKCOLOMKC-UHFFFAOYSA-N 7-chloro-1-[3-(methanesulfonamido)propyl]-n-(2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl)indole-3-carboxamide Chemical compound C1=CC=C2C(C(=O)NC3C4(C)CCC(C4)C3(C)C)=CN(CCCNS(C)(=O)=O)C2=C1Cl BPRNDMKCOLOMKC-UHFFFAOYSA-N 0.000 description 1
- DMBSXMWBALEIHV-UHFFFAOYSA-N 7-chloro-2,6-dimethyl-1-(3-methylsulfonylpropyl)-n-(2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl)indole-3-carboxamide Chemical compound C12=CC=C(C)C(Cl)=C2N(CCCS(C)(=O)=O)C(C)=C1C(=O)NC1C(C2)(C)CCC2C1(C)C DMBSXMWBALEIHV-UHFFFAOYSA-N 0.000 description 1
- UVCVFDKQYBRXLM-UHFFFAOYSA-N 7-chloro-2-methyl-1-(3-methylsulfonylpropyl)-n-(2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl)indole-3-carboxamide Chemical compound C12=CC=CC(Cl)=C2N(CCCS(C)(=O)=O)C(C)=C1C(=O)NC1C(C2)(C)CCC2C1(C)C UVCVFDKQYBRXLM-UHFFFAOYSA-N 0.000 description 1
- QQXKNUSLJURQNY-UHFFFAOYSA-N 7-fluoro-1-[3-(methanesulfonamido)propyl]-2,6-dimethyl-n-(2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl)indole-3-carboxamide Chemical compound C12=CC=C(C)C(F)=C2N(CCCNS(C)(=O)=O)C(C)=C1C(=O)NC1C(C2)(C)CCC2C1(C)C QQXKNUSLJURQNY-UHFFFAOYSA-N 0.000 description 1
- UOQAHYZRCQQRGH-UHFFFAOYSA-N 7-fluoro-1-[3-(methanesulfonamido)propyl]-2-methyl-n-(2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl)indole-3-carboxamide Chemical compound C12=CC=CC(F)=C2N(CCCNS(C)(=O)=O)C(C)=C1C(=O)NC1C(C2)(C)CCC2C1(C)C UOQAHYZRCQQRGH-UHFFFAOYSA-N 0.000 description 1
- FJCUUEOEZUUVCO-UHFFFAOYSA-N 7-fluoro-2,6-dimethyl-1-(3-methylsulfonylpropyl)-n-(2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl)indole-3-carboxamide Chemical compound C12=CC=C(C)C(F)=C2N(CCCS(C)(=O)=O)C(C)=C1C(=O)NC1C(C2)(C)CCC2C1(C)C FJCUUEOEZUUVCO-UHFFFAOYSA-N 0.000 description 1
- UGLZROXDOMZPQL-UHFFFAOYSA-N 7-fluoro-2-methyl-1-(3-methylsulfonylpropyl)-n-(2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl)indole-3-carboxamide Chemical compound C12=CC=CC(F)=C2N(CCCS(C)(=O)=O)C(C)=C1C(=O)NC1C(C2)(C)CCC2C1(C)C UGLZROXDOMZPQL-UHFFFAOYSA-N 0.000 description 1
- HAUUQWQHAMFQJJ-UHFFFAOYSA-N 7-methoxy-1-(2-morpholin-4-ylethyl)indole-3-carboxamide Chemical class C1=2C(OC)=CC=CC=2C(C(N)=O)=CN1CCN1CCOCC1 HAUUQWQHAMFQJJ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 201000008228 Ependymoblastoma Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 206010014968 Ependymoma malignant Diseases 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000009277 Neuroectodermal Tumors Diseases 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000005476 astroblastoma Diseases 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 206010004398 benign neoplasm of skin Diseases 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- IZZMPZQAQTXAHW-UHFFFAOYSA-N bicyclo[2.2.1]heptan-3-amine;hydrochloride Chemical compound Cl.C1CC2C(N)CC1C2 IZZMPZQAQTXAHW-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- SYZWSSNHPZXGML-UHFFFAOYSA-N dichloromethane;oxolane Chemical compound ClCCl.C1CCOC1 SYZWSSNHPZXGML-UHFFFAOYSA-N 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000010932 epithelial neoplasm Diseases 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- AYRVRXNNGNQGSX-UHFFFAOYSA-N n-(1-adamantyl)-7-chloro-1-[3-(methanesulfonamido)propyl]-2-methylindole-3-carboxamide Chemical compound C12=CC=CC(Cl)=C2N(CCCNS(C)(=O)=O)C(C)=C1C(=O)NC1(C2)CC(C3)CC2CC3C1 AYRVRXNNGNQGSX-UHFFFAOYSA-N 0.000 description 1
- ZWRBLCNTJHUCOR-UHFFFAOYSA-N n-(3-bicyclo[3.2.1]octanyl)-6,7-dichloro-1-[3-(methanesulfonamido)propyl]-2-methylindole-3-carboxamide Chemical compound C12=CC=C(Cl)C(Cl)=C2N(CCCNS(C)(=O)=O)C(C)=C1C(=O)NC1CC(C2)CCC2C1 ZWRBLCNTJHUCOR-UHFFFAOYSA-N 0.000 description 1
- SJQGOYXOXHUXDG-UHFFFAOYSA-N n-(3-bicyclo[3.2.1]octanyl)-6,7-dichloro-2-methyl-1-(3-methylsulfonylpropyl)indole-3-carboxamide Chemical compound C12=CC=C(Cl)C(Cl)=C2N(CCCS(C)(=O)=O)C(C)=C1C(=O)NC1CC(C2)CCC2C1 SJQGOYXOXHUXDG-UHFFFAOYSA-N 0.000 description 1
- DLWVVAFUKYGKSD-UHFFFAOYSA-N n-(3-bicyclo[3.2.1]octanyl)-6,7-difluoro-1-[3-(methanesulfonamido)propyl]-2-methylindole-3-carboxamide Chemical compound C12=CC=C(F)C(F)=C2N(CCCNS(C)(=O)=O)C(C)=C1C(=O)NC1CC(C2)CCC2C1 DLWVVAFUKYGKSD-UHFFFAOYSA-N 0.000 description 1
- SUIBUZCGXFBWAP-UHFFFAOYSA-N n-(3-bicyclo[3.2.1]octanyl)-6,7-difluoro-2-methyl-1-(3-methylsulfonylpropyl)indole-3-carboxamide Chemical compound C12=CC=C(F)C(F)=C2N(CCCS(C)(=O)=O)C(C)=C1C(=O)NC1CC(C2)CCC2C1 SUIBUZCGXFBWAP-UHFFFAOYSA-N 0.000 description 1
- TYWAQMHPGONGPG-UHFFFAOYSA-N n-(3-bicyclo[3.2.1]octanyl)-7-bromo-1-[3-(methanesulfonamido)propyl]-2,6-dimethylindole-3-carboxamide Chemical compound C12=CC=C(C)C(Br)=C2N(CCCNS(C)(=O)=O)C(C)=C1C(=O)NC1CC(C2)CCC2C1 TYWAQMHPGONGPG-UHFFFAOYSA-N 0.000 description 1
- RRGHODRTGSPUMQ-UHFFFAOYSA-N n-(3-bicyclo[3.2.1]octanyl)-7-bromo-1-[3-(methanesulfonamido)propyl]-2-methylindole-3-carboxamide Chemical compound C12=CC=CC(Br)=C2N(CCCNS(C)(=O)=O)C(C)=C1C(=O)NC1CC(C2)CCC2C1 RRGHODRTGSPUMQ-UHFFFAOYSA-N 0.000 description 1
- POLNPOKKQHAXCN-UHFFFAOYSA-N n-(3-bicyclo[3.2.1]octanyl)-7-bromo-2,6-dimethyl-1-(3-methylsulfonylpropyl)indole-3-carboxamide Chemical compound C12=CC=C(C)C(Br)=C2N(CCCS(C)(=O)=O)C(C)=C1C(=O)NC1CC(C2)CCC2C1 POLNPOKKQHAXCN-UHFFFAOYSA-N 0.000 description 1
- CEIGQRPFIWFHRY-UHFFFAOYSA-N n-(3-bicyclo[3.2.1]octanyl)-7-bromo-2-methyl-1-(3-methylsulfonylpropyl)indole-3-carboxamide Chemical compound C12=CC=CC(Br)=C2N(CCCS(C)(=O)=O)C(C)=C1C(=O)NC1CC(C2)CCC2C1 CEIGQRPFIWFHRY-UHFFFAOYSA-N 0.000 description 1
- OXLXIJGRQQMVPG-UHFFFAOYSA-N n-(3-bicyclo[3.2.1]octanyl)-7-chloro-1-[3-(methanesulfonamido)propyl]-2,6-dimethylindole-3-carboxamide Chemical compound C12=CC=C(C)C(Cl)=C2N(CCCNS(C)(=O)=O)C(C)=C1C(=O)NC1CC(C2)CCC2C1 OXLXIJGRQQMVPG-UHFFFAOYSA-N 0.000 description 1
- VCTAXEOCZDQPSQ-UHFFFAOYSA-N n-(3-bicyclo[3.2.1]octanyl)-7-chloro-1-[3-(methanesulfonamido)propyl]-2-methylindole-3-carboxamide Chemical compound C12=CC=CC(Cl)=C2N(CCCNS(C)(=O)=O)C(C)=C1C(=O)NC1CC(C2)CCC2C1 VCTAXEOCZDQPSQ-UHFFFAOYSA-N 0.000 description 1
- LWJXLPZIFQRMLO-UHFFFAOYSA-N n-(3-bicyclo[3.2.1]octanyl)-7-chloro-2,6-dimethyl-1-(3-methylsulfonylpropyl)indole-3-carboxamide Chemical compound C12=CC=C(C)C(Cl)=C2N(CCCS(C)(=O)=O)C(C)=C1C(=O)NC1CC(C2)CCC2C1 LWJXLPZIFQRMLO-UHFFFAOYSA-N 0.000 description 1
- IFEOTUKDEMRQJF-UHFFFAOYSA-N n-(3-bicyclo[3.2.1]octanyl)-7-chloro-2-methyl-1-(3-methylsulfonylpropyl)indole-3-carboxamide Chemical compound C12=CC=CC(Cl)=C2N(CCCS(C)(=O)=O)C(C)=C1C(=O)NC1CC(C2)CCC2C1 IFEOTUKDEMRQJF-UHFFFAOYSA-N 0.000 description 1
- AIIRWQPYAPPYSR-UHFFFAOYSA-N n-(3-bicyclo[3.2.1]octanyl)-7-fluoro-1-[3-(methanesulfonamido)propyl]-2,6-dimethylindole-3-carboxamide Chemical compound C12=CC=C(C)C(F)=C2N(CCCNS(C)(=O)=O)C(C)=C1C(=O)NC1CC(C2)CCC2C1 AIIRWQPYAPPYSR-UHFFFAOYSA-N 0.000 description 1
- JRZFZWFFISDVTE-UHFFFAOYSA-N n-(3-bicyclo[3.2.1]octanyl)-7-fluoro-1-[3-(methanesulfonamido)propyl]-2-methylindole-3-carboxamide Chemical compound C12=CC=CC(F)=C2N(CCCNS(C)(=O)=O)C(C)=C1C(=O)NC1CC(C2)CCC2C1 JRZFZWFFISDVTE-UHFFFAOYSA-N 0.000 description 1
- WKIVBVVPKZTTBQ-UHFFFAOYSA-N n-(3-bicyclo[3.2.1]octanyl)-7-fluoro-2,6-dimethyl-1-(3-methylsulfonylpropyl)indole-3-carboxamide Chemical compound C12=CC=C(C)C(F)=C2N(CCCS(C)(=O)=O)C(C)=C1C(=O)NC1CC(C2)CCC2C1 WKIVBVVPKZTTBQ-UHFFFAOYSA-N 0.000 description 1
- DGSQIYUAFZHTTF-UHFFFAOYSA-N n-(3-bicyclo[3.2.1]octanyl)-7-fluoro-2-methyl-1-(3-methylsulfonylpropyl)indole-3-carboxamide Chemical compound C12=CC=CC(F)=C2N(CCCS(C)(=O)=O)C(C)=C1C(=O)NC1CC(C2)CCC2C1 DGSQIYUAFZHTTF-UHFFFAOYSA-N 0.000 description 1
- ZSQURUGBZLHQDA-UHFFFAOYSA-N n-[3-(7-chloro-2-methylindol-1-yl)propyl]methanesulfonamide Chemical compound C1=CC(Cl)=C2N(CCCNS(C)(=O)=O)C(C)=CC2=C1 ZSQURUGBZLHQDA-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000027831 neuroepithelial neoplasm Diseases 0.000 description 1
- 208000029986 neuroepithelioma Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 238000004634 pharmacological analysis method Methods 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- PVFOMCVHYWHZJE-UHFFFAOYSA-N trichloroacetyl chloride Chemical compound ClC(=O)C(Cl)(Cl)Cl PVFOMCVHYWHZJE-UHFFFAOYSA-N 0.000 description 1
- 125000006168 tricyclic group Chemical group 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0215086A FR2847899B1 (fr) | 2002-11-29 | 2002-11-29 | Derives d'indole-3-carboxamide, leur preparation et leur application en therapeutique |
| PCT/FR2003/003499 WO2004050086A1 (fr) | 2002-11-29 | 2003-11-27 | Derives d'indole-3-carboxamide, leur preparation et leur application en therapeutique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006509781A true JP2006509781A (ja) | 2006-03-23 |
| JP2006509781A5 JP2006509781A5 (enExample) | 2007-01-25 |
Family
ID=32309872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004556430A Pending JP2006509781A (ja) | 2002-11-29 | 2003-11-27 | インドール−３−カルボキサミドの誘導体、それらの製造方法および治療用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7202268B2 (enExample) |
| EP (1) | EP1567150B1 (enExample) |
| JP (1) | JP2006509781A (enExample) |
| AT (1) | ATE439128T1 (enExample) |
| AU (1) | AU2003294092A1 (enExample) |
| DE (1) | DE60328819D1 (enExample) |
| FR (1) | FR2847899B1 (enExample) |
| WO (1) | WO2004050086A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008032764A1 (en) * | 2006-09-13 | 2008-03-20 | Kyowa Hakko Kirin Co., Ltd. | Fused heterocyclic derivative |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1833824B1 (en) * | 2004-12-21 | 2016-08-03 | AbbVie Inc. | 3-cycloalkylcarbonyl indoles as cannabinoid receptor ligands |
| FR2893615B1 (fr) * | 2005-11-18 | 2008-03-07 | Sanofi Aventis Sa | Derives de 3-acylindole, leur preparation et leur application en therapeutique |
| US8841334B2 (en) | 2006-05-31 | 2014-09-23 | Abbvie Inc. | Compounds as cannabinoid receptor ligands and uses thereof |
| CN101448800A (zh) | 2006-05-31 | 2009-06-03 | 艾博特公司 | 作为大麻素受体配体的新型化合物及其用途 |
| MX2009010363A (es) | 2007-03-28 | 2009-12-04 | Abbott Lab | Compuestos de 1,3-tiazol-2(3h)-ilideno como ligandos del receptor canabinoide. |
| US7872033B2 (en) | 2007-04-17 | 2011-01-18 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
| US8735434B2 (en) | 2007-05-18 | 2014-05-27 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
| US9193713B2 (en) | 2007-10-12 | 2015-11-24 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
| US8846730B2 (en) | 2008-09-08 | 2014-09-30 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
| TW201016692A (en) | 2008-09-16 | 2010-05-01 | Abbott Lab | Novel compounds as cannabinoid receptor ligands |
| WO2010077839A1 (en) * | 2008-12-15 | 2010-07-08 | Wyeth Llc (Formerly Known As Wyeth) | Substituted oxindol cb2 agonists for pain treatment |
| PA8854001A1 (es) | 2008-12-16 | 2010-07-27 | Abbott Lab | Compuestos novedosos como ligandos de receptores de canabinoides |
| CN108794379A (zh) * | 2017-04-26 | 2018-11-13 | 华东师范大学 | 1h-吲哚-2-甲酰胺衍生物及其制备方法和应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001058869A2 (en) * | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| WO2002042269A1 (fr) * | 2000-11-22 | 2002-05-30 | Sanofi-Synthelabo | Derives de 3-aroylindole et leur utilisation en tant qu'agonistes des recepteurs cb2 |
| WO2002060447A1 (en) * | 2001-01-29 | 2002-08-08 | University Of Connecticut | Receptor selective cannabimimetic aminoalkylindoles |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4973587A (en) * | 1990-03-08 | 1990-11-27 | Sterling Drug Inc. | 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method |
-
2002
- 2002-11-29 FR FR0215086A patent/FR2847899B1/fr not_active Expired - Fee Related
-
2003
- 2003-11-27 WO PCT/FR2003/003499 patent/WO2004050086A1/fr not_active Ceased
- 2003-11-27 EP EP03789510A patent/EP1567150B1/fr not_active Expired - Lifetime
- 2003-11-27 AT AT03789510T patent/ATE439128T1/de not_active IP Right Cessation
- 2003-11-27 DE DE60328819T patent/DE60328819D1/de not_active Expired - Lifetime
- 2003-11-27 AU AU2003294092A patent/AU2003294092A1/en not_active Abandoned
- 2003-11-27 JP JP2004556430A patent/JP2006509781A/ja active Pending
-
2005
- 2005-05-26 US US11/138,843 patent/US7202268B2/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001058869A2 (en) * | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| WO2002042269A1 (fr) * | 2000-11-22 | 2002-05-30 | Sanofi-Synthelabo | Derives de 3-aroylindole et leur utilisation en tant qu'agonistes des recepteurs cb2 |
| WO2002060447A1 (en) * | 2001-01-29 | 2002-08-08 | University Of Connecticut | Receptor selective cannabimimetic aminoalkylindoles |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008032764A1 (en) * | 2006-09-13 | 2008-03-20 | Kyowa Hakko Kirin Co., Ltd. | Fused heterocyclic derivative |
| US8236841B2 (en) | 2006-09-13 | 2012-08-07 | Kyowa Hakko Kirin Co., Ltd. | Fused heterocycle derivative |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003294092A1 (en) | 2004-06-23 |
| FR2847899B1 (fr) | 2006-04-28 |
| EP1567150A1 (fr) | 2005-08-31 |
| US20050288356A1 (en) | 2005-12-29 |
| DE60328819D1 (de) | 2009-09-24 |
| US7202268B2 (en) | 2007-04-10 |
| FR2847899A1 (fr) | 2004-06-04 |
| WO2004050086A1 (fr) | 2004-06-17 |
| ATE439128T1 (de) | 2009-08-15 |
| WO2004050086A8 (fr) | 2004-07-29 |
| EP1567150B1 (fr) | 2009-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006509781A (ja) | インドール−３−カルボキサミドの誘導体、それらの製造方法および治療用途 | |
| EP1546099B1 (en) | 3,6-disubstituted azabicyclo 3.1.0 hexane derivatives useful as muscarinic receptor antagonists | |
| JP2004514668A (ja) | ３−アロイルインドール誘導体およびｃｂ２レセプターアゴニストとしてのそれらの使用 | |
| KR20090127307A (ko) | 히스타민 ｈ３ 수용체 조절제로서의 테트라하이드로이소퀴놀린 화합물 | |
| JPH08507300A (ja) | 興奮性アミノ酸の拮抗剤としてのインドール誘導体 | |
| US8835633B2 (en) | Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives | |
| TW438773B (en) | Indole derivatives | |
| JP2009525312A (ja) | スルホンアミド誘導体、これの調製および治療への応用 | |
| JP2013006879A (ja) | 光学活性なテトラヒドロナフタレン誘導体 | |
| CN100406009C (zh) | 作为毒蕈碱受体拮抗剂的取代的氮杂双环己烷衍生物 | |
| JP5460614B2 (ja) | アゼチジン誘導体、それらの調製、およびそれらの治療における適用 | |
| MX2007004297A (es) | Antagonistas no peptidicos de bradiquinina y composiciones farmaceuticas de los mismos. | |
| JP2005530797A (ja) | インドール誘導体およびｃｂ２レセプターリガンドとしてのそれらの使用 | |
| CA2664057A1 (en) | Azetidine derivatives as muscarinic receptor antagonists | |
| JP5651683B2 (ja) | 置換された１−アルキルシンノリン−４（１ｈ）−オン誘導体、これらの調製およびこれらの治療用途 | |
| JP2009503063A (ja) | 呼吸器疾患の処置に有用なケモカイン受容体モジュレーターとしての新規ピペリジン誘導体 | |
| US20080319043A1 (en) | 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists | |
| TW201206910A (en) | Substituted N-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof | |
| JP5106410B2 (ja) | ３−アシルインドール誘導体、これらの調製および治療的使用 | |
| KR20140103968A (ko) | 2-(2-메틸아미노-피리미딘-4-일)-1h-인돌-5-카복실산 [(s)-1-카바모일-2-(페닐-피리미딘-2일-아미노)-에틸]-아미드의 결정 형태 | |
| JP2018527356A (ja) | 疼痛のための治療化合物及びその合成 | |
| AU2005235724A1 (en) | Compounds as CRRI antagonists | |
| JPH0967347A (ja) | 環状アミン誘導体及びそれを含有する医薬組成物 | |
| KR20050023401A (ko) | 무스카린 수용체 길항제로서 사용가능한 3,6-이치환된아자비시클로 [3.1.0]헥산 유도체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061124 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061124 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100413 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100712 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100817 |